Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan for JPY 21.5 Billion
Gujarat Themis Biosyn Ltd 路 Others (Uncategorized) 路 18 Sept 2026, 4:01 pm
Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan for JPY 21.5 Billion Gujarat Themis Biosyn completed the 100% acquisition of MicroBiopharm Japan on 18th Sep'26 via its subsidiary, Themis Biosyn Japan, for JPY 21.5 billion, funded via INR 475 crore equity and an INR 745 crore loan. The transaction is expected to be EPS accretive. MBJ registered FY26 revenue of JPY 9.5 billion across proprietary APIs, CDMO, and biologics, with ~40% derived outside Japan across three GMP-compliant plants. The acquisition expands GTBL鈥檚 precision fermentation capabilities, novel modalities, and global CDMO reach.
Original exchange filing (PDF)
More announcements from Gujarat Themis Biosyn Ltd
- Recording of Analysts Meet held on 16.11.2026 路 17 Nov 2026
- Please refer to the attached Analysts Presentation 路 16 Nov 2026
- Please refer to the attachment 路 16 Nov 2026
- Please refer to the intimation of resignation of Company Secretary & Compliance Officer. 路 15 Nov 2026
- Please refer to the attachment 路 14 Nov 2026
- Kindly refer to the Un-audited Standalone & Consolidated Financial Results for the quarter and half year ended 30.09.2026 路 14 Nov 2026
- Gujarat Themis Biosyn Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- Outcome of the Board Meeting held on 14.11.2026 路 14 Nov 2026
